PE20141699A1 - Derivados de espiroindolina como antagonistas del receptor de la hormona liberadora de gonadotropina - Google Patents
Derivados de espiroindolina como antagonistas del receptor de la hormona liberadora de gonadotropinaInfo
- Publication number
- PE20141699A1 PE20141699A1 PE2014001114A PE2014001114A PE20141699A1 PE 20141699 A1 PE20141699 A1 PE 20141699A1 PE 2014001114 A PE2014001114 A PE 2014001114A PE 2014001114 A PE2014001114 A PE 2014001114A PE 20141699 A1 PE20141699 A1 PE 20141699A1
- Authority
- PE
- Peru
- Prior art keywords
- methyl
- antagonists
- hormone receptor
- releasing hormone
- sulfonil
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D495/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms
- C07D495/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
- C07D495/10—Spiro-condensed systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/08—Drugs for disorders of the urinary system of the prostate
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
- A61P15/08—Drugs for genital or sexual disorders; Contraceptives for gonadal disorders or for enhancing fertility, e.g. inducers of ovulation or of spermatogenesis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
- A61P15/16—Masculine contraceptives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
- A61P15/18—Feminine contraceptives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
- A61P5/02—Drugs for disorders of the endocrine system of the hypothalamic hormones, e.g. TRH, GnRH, CRH, GRH, somatostatin
- A61P5/04—Drugs for disorders of the endocrine system of the hypothalamic hormones, e.g. TRH, GnRH, CRH, GRH, somatostatin for decreasing, blocking or antagonising the activity of the hypothalamic hormones
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
- A61P5/06—Drugs for disorders of the endocrine system of the anterior pituitary hormones, e.g. TSH, ACTH, FSH, LH, PRL, GH
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
- A61P5/06—Drugs for disorders of the endocrine system of the anterior pituitary hormones, e.g. TSH, ACTH, FSH, LH, PRL, GH
- A61P5/08—Drugs for disorders of the endocrine system of the anterior pituitary hormones, e.g. TSH, ACTH, FSH, LH, PRL, GH for decreasing, blocking or antagonising the activity of the anterior pituitary hormones
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
- A61P5/24—Drugs for disorders of the endocrine system of the sex hormones
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D491/00—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
- C07D491/02—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains two hetero rings
- C07D491/10—Spiro-condensed systems
- C07D491/107—Spiro-condensed systems with only one oxygen atom as ring hetero atom in the oxygen-containing ring
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Veterinary Medicine (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Public Health (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Endocrinology (AREA)
- Reproductive Health (AREA)
- Diabetes (AREA)
- Immunology (AREA)
- Gynecology & Obstetrics (AREA)
- Dermatology (AREA)
- Pregnancy & Childbirth (AREA)
- Urology & Nephrology (AREA)
- Pulmonology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
- Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)
Abstract
SE REFIERE A COMPUESTOS DERIVADOS DE ESPIROINDOLINA DE FORMULA (I) DONDE W ES O U S(O)x, DONDE x ES DE 0 A 2; R1 ES H, ALQUILO(C1-C6), CICLOALQUILO(C3-C10), ARILO, ENTRE OTROS; R2 ES ARILO O HETEROARILO OPCIONALMENTE SUSTITUIDO CON R4, EN DONDE R4 ES HALOGENO, HIDROXI, C(O)NH2, ENTRE OTROS; R3 ES C(O)N(R5a)(R5b), N(H)C(O)R6, ENTRE OTROS, EN DONDE R5a, R5b Y R6 SON CADA UNO H, ALQUILO(C1-C6), ALQUENILO(C2-C6), ENTRE OTROS. SON COMPUESTOS PREFERIDOS: N-[(3-CLOROPIRIDIN-2-IL)METIL]-1-[(4-FLUOROFENIL)SULFONIL]-2-METIL-1,2,2',3',5',6'-HEXAHIDROESPIRO[INDOL-3,4'-PIRAN]-5-CARBOXAMIDA; N-(2-CLOROBENCIL)-1-[(4-FLUOROFENIL)SULFONIL]-2-METIL-1,2,2',3',5',6'-HEXAHIDROESPIRO[INDOL-3,4'-PIRAN]-5-CARBOXAMIDA; 1-[(4-FLUOROFENIL)SULFONIL]-2-METIL-N-{[3-(TRIFLUOROMETIL)PIRIDIN-2-IL]METIL}-1,2,2',3',5',6'-HEXAHIDROESPIRO[INDOL-3,4'-PIRAN]-5-CARBOXAMIDA; ENTRE OTROS. TAMBIEN SE REFIERE A UNA COMPOSICION FARMACEUTICA. DICHOS COMPUESTOS SON ANTAGONISTAS DEL RECEPTOR DE LA HORMONA LIBERADORA DE GONADOTROPINA (GnRH) SIENDO UTILES EN EL TRATAMIENTO DE ENDOMETRIOSIS, FIBROIDES EN EL UTERO, OVARIO POLIQUISTICO
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
EP12151291 | 2012-01-16 |
Publications (1)
Publication Number | Publication Date |
---|---|
PE20141699A1 true PE20141699A1 (es) | 2014-11-29 |
Family
ID=47559493
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PE2014001114A PE20141699A1 (es) | 2012-01-16 | 2013-01-15 | Derivados de espiroindolina como antagonistas del receptor de la hormona liberadora de gonadotropina |
Country Status (25)
Country | Link |
---|---|
US (1) | US20140357655A1 (es) |
EP (1) | EP2804867A1 (es) |
JP (1) | JP2015503607A (es) |
KR (1) | KR20140112075A (es) |
CN (1) | CN104169287A (es) |
AP (1) | AP2014007738A0 (es) |
AU (1) | AU2013211091A1 (es) |
BR (1) | BR112014017483A8 (es) |
CA (1) | CA2860986A1 (es) |
CL (1) | CL2014001871A1 (es) |
CO (1) | CO7010832A2 (es) |
CR (1) | CR20140343A (es) |
CU (1) | CU20140088A7 (es) |
DO (1) | DOP2014000167A (es) |
EA (1) | EA201491344A1 (es) |
GT (1) | GT201400153A (es) |
HK (1) | HK1199878A1 (es) |
IL (1) | IL233485A0 (es) |
MA (1) | MA35867B1 (es) |
MX (1) | MX2014008630A (es) |
PE (1) | PE20141699A1 (es) |
PH (1) | PH12014501616A1 (es) |
SG (1) | SG11201403749VA (es) |
TN (1) | TN2014000306A1 (es) |
WO (1) | WO2013107743A1 (es) |
Families Citing this family (8)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
AR095785A1 (es) * | 2013-04-09 | 2015-11-11 | Bayer Pharma AG | Derivados de espiroindolina y composiciones farmacéutica de los mismos |
WO2015007606A1 (en) * | 2013-07-15 | 2015-01-22 | Bayer Pharma Aktiengesellschaft | Spiroindoline derivatives and pharmaceutical compositions thereof |
WO2015082374A1 (en) * | 2013-12-05 | 2015-06-11 | Bayer Pharma Aktiengesellschaft | Spiroindoline-thiopyran-imine-oxide derivatives as gonadotropin-releasing hormone receptor antagonists and pharmaceutical compositions thereof |
EP2881391A1 (en) | 2013-12-05 | 2015-06-10 | Bayer Pharma Aktiengesellschaft | Spiroindoline carbocycle derivatives and pharmaceutical compositions thereof |
WO2015091315A1 (en) * | 2013-12-19 | 2015-06-25 | Bayer Pharma Aktiengesellschaft | Spiro[indolin-3,4'-piperidine] derivatives as gnrh receptor antagonists |
EP3339846B1 (en) * | 2016-12-22 | 2020-12-09 | Malvern Panalytical B.V. | Method of measuring properties of a thin film stack |
CN110996956A (zh) | 2017-06-05 | 2020-04-10 | 奥布赛瓦股份公司 | 用于治疗子宫内膜异位症的促性腺激素释放激素拮抗剂给药方案 |
CN107840851A (zh) * | 2017-12-21 | 2018-03-27 | 扬州大学 | 吲哚螺吡咯嗪化合物及其合成方法 |
Family Cites Families (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US5849780A (en) * | 1992-01-30 | 1998-12-15 | Sanofi | 1-benzenesulfonyl-1-1,3-dihydroindol-2-one derivatives, their preparation and pharmaceutical compositions in which they are present |
TW200522944A (en) * | 2003-12-23 | 2005-07-16 | Lilly Co Eli | CB1 modulator compounds |
-
2013
- 2013-01-15 CN CN201380014647.3A patent/CN104169287A/zh active Pending
- 2013-01-15 EP EP13700304.2A patent/EP2804867A1/en not_active Withdrawn
- 2013-01-15 KR KR1020147022494A patent/KR20140112075A/ko not_active Application Discontinuation
- 2013-01-15 AU AU2013211091A patent/AU2013211091A1/en not_active Abandoned
- 2013-01-15 BR BR112014017483A patent/BR112014017483A8/pt not_active Application Discontinuation
- 2013-01-15 EA EA201491344A patent/EA201491344A1/ru unknown
- 2013-01-15 WO PCT/EP2013/050676 patent/WO2013107743A1/en active Application Filing
- 2013-01-15 AP AP2014007738A patent/AP2014007738A0/xx unknown
- 2013-01-15 US US14/371,312 patent/US20140357655A1/en not_active Abandoned
- 2013-01-15 MX MX2014008630A patent/MX2014008630A/es unknown
- 2013-01-15 PE PE2014001114A patent/PE20141699A1/es not_active Application Discontinuation
- 2013-01-15 JP JP2014551648A patent/JP2015503607A/ja active Pending
- 2013-01-15 CA CA2860986A patent/CA2860986A1/en not_active Abandoned
- 2013-01-15 SG SG11201403749VA patent/SG11201403749VA/en unknown
-
2014
- 2014-07-02 IL IL233485A patent/IL233485A0/en unknown
- 2014-07-11 PH PH12014501616A patent/PH12014501616A1/en unknown
- 2014-07-15 MA MA37214A patent/MA35867B1/fr unknown
- 2014-07-15 TN TNP2014000306A patent/TN2014000306A1/fr unknown
- 2014-07-15 CL CL2014001871A patent/CL2014001871A1/es unknown
- 2014-07-16 DO DO2014000167A patent/DOP2014000167A/es unknown
- 2014-07-16 GT GT201400153A patent/GT201400153A/es unknown
- 2014-07-16 CO CO14154059A patent/CO7010832A2/es not_active Application Discontinuation
- 2014-07-16 CU CU2014000088A patent/CU20140088A7/es unknown
- 2014-07-16 CR CR20140343A patent/CR20140343A/es unknown
-
2015
- 2015-01-13 HK HK15100323.1A patent/HK1199878A1/xx unknown
Also Published As
Publication number | Publication date |
---|---|
IL233485A0 (en) | 2014-08-31 |
CN104169287A (zh) | 2014-11-26 |
TN2014000306A1 (en) | 2015-12-21 |
AU2013211091A1 (en) | 2014-08-07 |
SG11201403749VA (en) | 2014-07-30 |
BR112014017483A2 (pt) | 2017-06-13 |
CR20140343A (es) | 2014-09-08 |
EA201491344A1 (ru) | 2015-04-30 |
JP2015503607A (ja) | 2015-02-02 |
US20140357655A1 (en) | 2014-12-04 |
KR20140112075A (ko) | 2014-09-22 |
AP2014007738A0 (en) | 2014-07-31 |
PH12014501616A1 (en) | 2014-10-13 |
BR112014017483A8 (pt) | 2017-07-04 |
EP2804867A1 (en) | 2014-11-26 |
WO2013107743A1 (en) | 2013-07-25 |
HK1199878A1 (en) | 2015-07-24 |
CO7010832A2 (es) | 2014-07-31 |
CL2014001871A1 (es) | 2014-11-03 |
CA2860986A1 (en) | 2013-07-25 |
DOP2014000167A (es) | 2014-08-31 |
MX2014008630A (es) | 2014-08-29 |
CU20140088A7 (es) | 2014-12-26 |
MA35867B1 (fr) | 2014-12-01 |
GT201400153A (es) | 2015-05-22 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
PE20141699A1 (es) | Derivados de espiroindolina como antagonistas del receptor de la hormona liberadora de gonadotropina | |
PE20110237A1 (es) | Derivados de ciclohexilamida como antagonistas del receptor del factor de liberacion de corticotropina (crf-1) | |
PH12017501140A1 (en) | TETRAHYDRO-PYRIDO[3,4-b]INDOLE ESTROGEN RECEPTOR MODULATORS AND USES THEREOF | |
PE20121522A1 (es) | Derivados de acido 5-alquinil-3-amida-2-tiofeno-carboxilico como inhibidores del virus flaviviridae | |
EA201270467A1 (ru) | Полициклические соединения в качестве антагонистов рецепторов лизофосфатидной кислоты | |
PE20120693A1 (es) | Compuestos heterociclos como moduladores de la piruvato cinasa m2 (pkm2) | |
PE20120207A1 (es) | Derivados de naftaleno, como inhibidores de hcv ns5a | |
PE20090237A1 (es) | Derivados de sulfonamidas como inhibidores de los canales de sodio | |
EA201100691A1 (ru) | Антагонисты рецепторов лизофосфатидной кислоты | |
PE20070642A1 (es) | Compuestos derivados de pirazol como antagonistas del receptor de la progesterona | |
PE20080275A1 (es) | Derivados de 5h-benzo[4,5]ciclohepta[1,2]piridina como inhibidores de tirosina quinasa | |
PE20110793A1 (es) | Derivados de (3-(4-cianofenil)-1h-pirazol-5 carboxamida como antagonistas del receptor de progesterona | |
PE20140302A1 (es) | Inhibidores del virus de la hepatitis c | |
PE20121050A1 (es) | Compuestos de n-(1-(4-(1h-pirazol-5-il)ftalazin-1-il)piperidin-4-il)-benzamida sustituidos como antagonistas de la trayectoria hedgehog | |
PE20090876A1 (es) | Nuevos derivados de 6-aril/heteroalquiloxi benzotiazol y bencimidazol, su procedimiento de preparacion, su aplicacion como medicamentos, composiciones farmaceuticas y nueva utilizacion principalmente como inhibidores de cmet | |
PE20060625A1 (es) | Derivados de benzazepina como antagonistas y/o agonistas del receptor h3 de histamina | |
PE20070586A1 (es) | Compuestos de (4-piperidinil)-1,3-dihidro-2h-bencimidazol-2-ona sustituidos como agonistas del receptor muscarinico m1 | |
PE20081665A1 (es) | Antagonistas del receptor de dopamina 2 de rapida disociacion | |
PH12016500989A1 (en) | Crystalline form of (s)-(2-(6-chloro-7-methyl-1h-benzo[d]imidazol-2-yl)-2-methylpyrrolidin-1 -yl)(5-methoxy-2-(2h-1,2,3-triazol-2-yl)phenyl)methanone as orexin receptor antagonists | |
PE20140610A1 (es) | Derivados de la piperidina 3-espirociclica como agonistas de receptores de la ghrelina | |
EA201600435A1 (ru) | Кристаллическая форма (s)-(2-(6-хлор-7-метил-1н-бензо[d]имидазол-2-ил)-2-метилпирролидин-1-ил)(5-метокси-2-(2h-1,2,3-триазол-2-ил)фенил)метанона и ее применение в качестве антагонистов орексинового рецептора | |
CL2011000533A1 (es) | Compuestos derivados de isoquinolina sustituida; antagonista nk3; composicion farmaceutica que lo comprende; y uso en el tratamiento de enfermedades tales como psicosis, esquizofrenia, alzheimer, parkinson, entre otras. | |
PE20120766A1 (es) | Derivados de quinoxalina como inhibidores de tumores | |
PE20090115A1 (es) | Derivados de indol-2-il-piperazin-1-il-metanona | |
AR046427A1 (es) | Sales de acido naftalen -1,5- disulfonico de un compuesto de 4- amino -1- ( piridilmetil) piperidina |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
FD | Application declared void or lapsed |